Dr. Tracy Beth Hogue Resigns from FDA Leadership Role
Dr. Tracy Beth Hogue has announced her resignation as head of the FDA division overseeing both over-the-counter and prescription drugs, as confirmed by officials from the Department of Health and Human Services (HHS).
Background on Hogue’s Tenure
Hogue, a sports medicine doctor known for her controversial stance on COVID-19 vaccinations for children, served as the acting director of the FDA’s Center for Drug Evaluation and Research for approximately five months. During her time in this position, she became the fifth individual to occupy this role under the Trump administration.
Transition in Leadership
Following Hogue’s departure, Michael Davis, the deputy director of CDER, will take on the role of acting director. Meanwhile, the position previously held by Marty McCulley, who resigned in opposition to the administration’s expansion of flavored e-cigarettes, will be temporarily filled by Kyle Diamantas, the FDA’s leading food regulator.
Seeking New Leadership Talent
HHS has not yet responded to inquiries regarding Hogue’s resignation. In a statement issued on Friday, HHS spokeswoman Emily Hilliard noted that the administration is dedicated to finding strong candidates for key leadership roles throughout HHS, particularly within the FDA. The focus is on attracting experienced professionals who can enhance agency operations, advance critical reforms, and uphold public trust.
Public Health Leadership Continuity
Despite the leadership transition, Hilliard assured that both the FDA and HHS remain committed to addressing urgent public health challenges with robust leadership in place. The agencies are working proactively to manage ongoing public health situations effectively.
Controversial Decisions During Hogue’s Leadership
During her brief tenure, Hogue was a polarizing figure, often challenging the FDA’s decisions. As early as June of last year, she expressed doubts regarding the safety of an FDA-approved treatment for respiratory syncytial virus (RSV) in infants. Moreover, just prior to her resignation, she opposed the FDA’s expedited review of Sanofi’s diabetes drug teplizumab, highlighting ongoing internal disputes.
Further Public Health Policies Under Scrutiny
Additionally, Hogue co-authored a scientific assessment used by the Trump administration to revise the childhood vaccination schedule, aligning it more closely with Denmark’s. In January, the administration recommended vaccinating all children against what were previously 18 diseases, though a federal judge temporarily blocked the changes in March due to ongoing legal challenges. At a vaccine advisory meeting, Hogue argued that reducing the universal vaccination of children would minimize exposure to aluminum, despite longstanding scientific evidence affirming the safety of aluminum salts present in vaccines.
